Saurabh Malhotra

@NotNoninvasive

Imaging Cardiologist, Director of Advanced Cardiac Imaging

Chicago, IL
Vrijeme pridruživanja: travanj 2018.

Tweetovi

Blokirali ste korisnika/cu @NotNoninvasive

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @NotNoninvasive

  1. 30. sij
    Poništi
  2. 30. sij

    Nice run down of the results. I am still unsure as to what is new here.

    Poništi
  3. 25. sij
    Poništi
  4. proslijedio/la je Tweet
    2. sij

    Given no peer reviewed paper yet, seems premature. Besides, ISCHEMIA did not randomize to CCTA vs. stress. All trials which did are essentially neutral. Only thing that is for sure, is that we should do less not more & CCTA usually is a path to more not less..

    Poništi
  5. 16. pro 2019.
    Poništi
  6. proslijedio/la je Tweet
    12. pro 2019.

    Great presentation by Dr Yasmeen Golzar from at UIC Cardiology Grand Rounds

    , , i još njih 6
    Poništi
  7. proslijedio/la je Tweet
    11. pro 2019.
    Poništi
  8. proslijedio/la je Tweet
    11. pro 2019.
    Poništi
  9. proslijedio/la je Tweet
    8. pro 2019.

    Is this all that bad?

    Prikaži ovu nit
    Poništi
  10. proslijedio/la je Tweet
    8. pro 2019.

    "The way forward... is to curb future pension benefits." It's inevitable. Let's get serious about it now. MT Editorial: alert: Why Chicago skyscrapers and your home are worth less

    Poništi
  11. proslijedio/la je Tweet
    22. stu 2019.
    Poništi
  12. 22. stu 2019.

    Agree. I doubt if anything will. Let’s channel the tax payer money towards systems improvement rather than trying to change individual whim, as majority of patients do not conform to a particular RCT. I am not sure if we can break the risk reduction ceiling anymore.

    Poništi
  13. proslijedio/la je Tweet
    Odgovor korisnicima i sljedećem broju korisnika:

    Here is to stopping DOT & pilot screening! Unnecessary testing is harmful

    Poništi
  14. proslijedio/la je Tweet
    21. stu 2019.
    Odgovor korisnicima i sljedećem broju korisnika:

    In the words of , common sense must prevail.

    Poništi
  15. 21. stu 2019.

    Based on information that we currently have, answer would be you don’t have to. Additionally, since pt is asymptomatic after the great job u did with OMT, then even the QOL benefit of revasc goes away.

    Poništi
  16. 20. stu 2019.
    Poništi
  17. 20. stu 2019.

    How does an asymp. patient make it to any testing? Preop for high risk surgery perhaps. RCTs cherry pick pts. Many may not meet inclusion criteria. Pts. with renal failure excluded - no CT. What to do about them? Do they not have ?

    Poništi
  18. 20. stu 2019.

    I agree with your sentiment. But this is in ref. to , which included a fraction of patients that we see. CT is an exceptional test, but was only used to rule out that we are not putting patients with ischemia with LM disease on OMT alone. Common sense needs to prevail

    Poništi
  19. 20. stu 2019.
    Poništi
  20. 19. stu 2019.
    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·